MIM
SUPN icon

Macroview Investment Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Macroview Investment Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-248
Closed -$7.18K – 696
2023
Q4 		$7.18K Buy
+248
New +$6.58K 0.01% 341
2021
Q3 		– Sell
-1,200
Closed -$37K – 463
2021
Q2 		$37K Buy
+1,200
New +$36.8K 0.05% 109

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

Macroview Investment Management's SUPN Position: Q1 2024 in Review

Macroview Investment Management sold out of Supernus Pharmaceuticals (SUPN) in Q1 2024, closing a stake of 248 shares — an estimated $7.18K sold.

Macroview Investment Management first reported a position in SUPN in Q2 2021 and held it in 2 quarters. The position peaked at $37K in Q2 2021. 250 funds tracked by Wall St. Rank hold SUPN as of Q1 2024.

  • Macroview Investment Management reported no remaining Supernus Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Macroview Investment Management sold 248 Supernus Pharmaceuticals shares in Q1 2024, an estimated $7.18K.
  • Macroview Investment Management first reported a position in Supernus Pharmaceuticals in Q2 2021 and held it in 2 quarters.
  • Macroview Investment Management's Supernus Pharmaceuticals position peaked at $37K in Q2 2021.
  • 250 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2024.

Based on Macroview Investment Management's 13F filing for Q1 2024, filed 30 Apr 2024.